Difference between revisions of "Team:NTU-Singapore/Medals"
| Line 60: | Line 60: | ||
<strong>1. </strong> <strong><u>Validated Part</u></strong><br> | <strong>1. </strong> <strong><u>Validated Part</u></strong><br> | ||
</p> | </p> | ||
| − | <p style="padding-top:0.5em; padding-left:1. | + | <p style="padding-top:0.5em; padding-left:1.2em;"> |
Check! We have validated and well characterised the dCas13b-ADAR2DD (<a href="http://parts.igem.org/Part:BBa_K2818002" target="_blank">BBa_K2818002</a>) and dCas13d-ADAR2DD (<a href="http://parts.igem.org/Part:BBa_K2818001" target="_blank">BBa_K2818001</a>). See our results for validating and characterising important design parameters of these parts <a href="https://2018.igem.org/Team:NTU-Singapore/Basic_Part" target="_blank">here</a>. | Check! We have validated and well characterised the dCas13b-ADAR2DD (<a href="http://parts.igem.org/Part:BBa_K2818002" target="_blank">BBa_K2818002</a>) and dCas13d-ADAR2DD (<a href="http://parts.igem.org/Part:BBa_K2818001" target="_blank">BBa_K2818001</a>). See our results for validating and characterising important design parameters of these parts <a href="https://2018.igem.org/Team:NTU-Singapore/Basic_Part" target="_blank">here</a>. | ||
</p> | </p> | ||
| Line 66: | Line 66: | ||
<strong>2. </strong> <strong><u>Collaboration</u></strong><br> | <strong>2. </strong> <strong><u>Collaboration</u></strong><br> | ||
</p> | </p> | ||
| − | <p style="padding-top:0.5em; padding-left:1. | + | <p style="padding-top:0.5em; padding-left:1.2em;"> |
Check! This year we have collaborated with both <a href="https://2018.igem.org/Team:NUS_Singapore-A/Collaborations" target="_blank">NUS-Singapore-A</a> and <a href="https://2018.igem.org/Team:UI_Indonesia/Collaborations" target="_blank">UI-Indonesia</a>. See our details for collaboration <a href="https://2018.igem.org/Team:NTU-Singapore/Collaborations" target="_blank">here</a>. | Check! This year we have collaborated with both <a href="https://2018.igem.org/Team:NUS_Singapore-A/Collaborations" target="_blank">NUS-Singapore-A</a> and <a href="https://2018.igem.org/Team:UI_Indonesia/Collaborations" target="_blank">UI-Indonesia</a>. See our details for collaboration <a href="https://2018.igem.org/Team:NTU-Singapore/Collaborations" target="_blank">here</a>. | ||
</p> | </p> | ||
| Line 72: | Line 72: | ||
<strong>3. </strong> <strong><u>Human Practice</u></strong><br> | <strong>3. </strong> <strong><u>Human Practice</u></strong><br> | ||
</p> | </p> | ||
| − | <p style="padding-top:0.5em; padding-left:1. | + | <p style="padding-top:0.5em; padding-left:1.2em;"> |
Check! This year our human practice focuses on investigating the public attitude of gene editing in Singapore and in the Aisa region. We have conducted a series of social studies and engagement with the public. See our human practice <a href="https://2018.igem.org/Team:NTU-Singapore/Human_Practices" target="_blank">here</a>. | Check! This year our human practice focuses on investigating the public attitude of gene editing in Singapore and in the Aisa region. We have conducted a series of social studies and engagement with the public. See our human practice <a href="https://2018.igem.org/Team:NTU-Singapore/Human_Practices" target="_blank">here</a>. | ||
</p> | </p> | ||
| Line 84: | Line 84: | ||
<strong>1. </strong> <strong><u>Integrated Human Practices</u></strong><br> | <strong>1. </strong> <strong><u>Integrated Human Practices</u></strong><br> | ||
</p> | </p> | ||
| − | <p style="padding-top:0.5em; padding-left:1. | + | <p style="padding-top:0.5em; padding-left:1.3em;"> |
Check! Through interactions with different stakeholders in the discussion of gene editing, we have integrated the conclusions we draw from human practice to evolve our project. After human practice, we felt the great importance to develop RNA editing technology and realise better transcriptome analysis and include them as a part of our project. See our integrated human practice <a href="https://2018.igem.org/Team:NTU-Singapore/IHP" target="_blank">here</a>. | Check! Through interactions with different stakeholders in the discussion of gene editing, we have integrated the conclusions we draw from human practice to evolve our project. After human practice, we felt the great importance to develop RNA editing technology and realise better transcriptome analysis and include them as a part of our project. See our integrated human practice <a href="https://2018.igem.org/Team:NTU-Singapore/IHP" target="_blank">here</a>. | ||
</p> | </p> | ||
| Line 90: | Line 90: | ||
<strong>2. </strong> <strong><u>Improvement on a Part</u></strong><br> | <strong>2. </strong> <strong><u>Improvement on a Part</u></strong><br> | ||
</p> | </p> | ||
| − | <p style="padding-top:0.5em; padding-left:1. | + | <p style="padding-top:0.5em; padding-left:1.3em;"> |
Check! This year, we use DNA binders and DNA binding peptides to futher improve the transcriptional activation activity of the truncated dCas9 constructs. The new and improved truncated dCas9 broke through the threshold for improvement we faced in the previous year. See our part improvement <a href="https://2018.igem.org/Team:NTU-Singapore/Improve" target="_blank">here</a>. | Check! This year, we use DNA binders and DNA binding peptides to futher improve the transcriptional activation activity of the truncated dCas9 constructs. The new and improved truncated dCas9 broke through the threshold for improvement we faced in the previous year. See our part improvement <a href="https://2018.igem.org/Team:NTU-Singapore/Improve" target="_blank">here</a>. | ||
</p> | </p> | ||
| Line 96: | Line 96: | ||
<strong>3. </strong> <strong><u>Demonstration</u></strong><br> | <strong>3. </strong> <strong><u>Demonstration</u></strong><br> | ||
</p> | </p> | ||
| − | <p style="padding-top:0.5em; padding-left:1. | + | <p style="padding-top:0.5em; padding-left:1.3em;"> |
Check! We have demonstrated the successful targeting and A-to-I base change by our dCas13b-ADAR2<span class="small-letter">DD</span> and dCas13d-ADAR2<span class="small-letter">DD</span> on endogeneous gene in cancer cell model, illustrating great potential for the application of the constructs for therapeutic purposes. See our real life demostration <a href="https://2018.igem.org/Team:NTU-Singapore/Demonstrate" target="_blank">here</a>. | Check! We have demonstrated the successful targeting and A-to-I base change by our dCas13b-ADAR2<span class="small-letter">DD</span> and dCas13d-ADAR2<span class="small-letter">DD</span> on endogeneous gene in cancer cell model, illustrating great potential for the application of the constructs for therapeutic purposes. See our real life demostration <a href="https://2018.igem.org/Team:NTU-Singapore/Demonstrate" target="_blank">here</a>. | ||
</p> | </p> | ||
Revision as of 02:38, 17 October 2018
Medal Criteria
Bronze Criteria
1. Register for iGEM, have a great iGEM season, and attend the Giant Jamboree.
Check! See our team information here.
2. Competition Deliverables
Check! You can visit our booth to see our poster and presentation at the Giant Jamboree. Visit our Wiki and Judging form clicking on the links.
3. Attributions
Check! See our attributions here.
4. InterLab Measurement
Check! We have completed the interlab measurement this year. See our results here!
Silver Criteria
1. Validated Part
Check! We have validated and well characterised the dCas13b-ADAR2DD (BBa_K2818002) and dCas13d-ADAR2DD (BBa_K2818001). See our results for validating and characterising important design parameters of these parts here.
2. Collaboration
Check! This year we have collaborated with both NUS-Singapore-A and UI-Indonesia. See our details for collaboration here.
3. Human Practice
Check! This year our human practice focuses on investigating the public attitude of gene editing in Singapore and in the Aisa region. We have conducted a series of social studies and engagement with the public. See our human practice here.
Gold Criteria
1. Integrated Human Practices
Check! Through interactions with different stakeholders in the discussion of gene editing, we have integrated the conclusions we draw from human practice to evolve our project. After human practice, we felt the great importance to develop RNA editing technology and realise better transcriptome analysis and include them as a part of our project. See our integrated human practice here.
2. Improvement on a Part
Check! This year, we use DNA binders and DNA binding peptides to futher improve the transcriptional activation activity of the truncated dCas9 constructs. The new and improved truncated dCas9 broke through the threshold for improvement we faced in the previous year. See our part improvement here.
3. Demonstration
Check! We have demonstrated the successful targeting and A-to-I base change by our dCas13b-ADAR2DD and dCas13d-ADAR2DD on endogeneous gene in cancer cell model, illustrating great potential for the application of the constructs for therapeutic purposes. See our real life demostration here.